FDA grants Sanofi's blockbuster priority review in a new indication
Sanofi’s drug Dupixent has now received the US health authority’s Breakthrough Therapy, Orphan Drug and Priority Review designations, the latter of which in a new indication for people with inflamed esophagi due to allergies.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
French Sanofi has been granted Priority Review by the US Food and Drug Administration (FDA) for Dupixent (dupilumab) in the indication for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus, the company has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Sanofi sees higher earnings as blockbuster skin drug soars
For subscribers
